Browse the corpus

Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.

• 100 years of insulin: celebrating the past, present and future of diabetes therapy.1 passage
• 11 clinical trials that will shape medicine in 2023.17 passages
• A 'mix and match' approach to SARS-CoV-2 vaccination.1 passage
• A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.52 passages
• A H3K27M-targeted vaccine in adults with diffuse midline glioma.52 passages
• A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity.1 passage
• A T cell resilience model associated with response to immunotherapy in multiple tumor types.1 passage
• A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial.81 passages
• A brain cell atlas integrating single-cell transcriptomes across human brain regions.80 passages
• A candidate antibody drug for prevention of malaria.113 passages
• A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.1 passage
• A cellular reference atlas of the human lung.10 passages
• A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.111 passages
• A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.1 passage
• A clinical environment simulator for dynamic AI evaluation.1 passage
• A cognitive layer architecture to support large-language model performance in psychotherapy interactions.1 passage
• A combination typhoid and non-typhoidal Salmonella polysaccharide conjugate vaccine in healthy adults: a randomized, placebo-controlled phase 1 trial.58 passages
• A consensus blood transcriptomic framework for sepsis.60 passages
• A consensus immune dysregulation framework for sepsis and critical illnesses.85 passages
• A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial.61 passages
• A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia.122 passages
• A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories.85 passages
• A deep learning system for predicting time to progression of diabetic retinopathy.79 passages
• A deep-learning algorithm to classify skin lesions from mpox virus infection.70 passages
• A digital health algorithm to guide antibiotic prescription in pediatric outpatient care: a cluster randomized controlled trial.60 passages
• A digital mask to safeguard patient privacy.78 passages
• A fasting-mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial.1 passage
• A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.59 passages
• A first-in-human study of quantitative ultrasound to assess transplant kidney fibrosis.62 passages
• A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.110 passages
• A foundation model for clinical-grade computational pathology and rare cancers detection.118 passages
• A foundation model for clinician-centered drug repurposing.106 passages
• A framework for microbiome science in public health.1 passage
• A framework for sharing of clinical and genetic data for precision medicine applications.130 passages
• A full life cycle biological clock based on routine clinical data and its impact in health and diseases.76 passages
• A generalist medical language model for disease diagnosis assistance.1 passage
• A generalist vision-language foundation model for diverse biomedical tasks.1 passage
• A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.52 passages
• A global initiative to deliver precision health in diabetes.1 passage
• A global survey of potential acceptance of a COVID-19 vaccine.26 passages
• A guide to immunotherapy for COVID-19.1 passage
• A gut microbial signature for combination immune checkpoint blockade across cancer types.88 passages
• A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials.41 passages
• A high-performance brain-computer interface for finger decoding and quadcopter game control in an individual with paralysis.91 passages
• A human three-dimensional neural-perivascular 'assembloid' promotes astrocytic development and enables modeling of SARS-CoV-2 neuropathology.1 passage
• A joint international consensus statement for measuring quality of survival for patients with childhood cancer.1 passage
• A large language model for complex cardiology care.58 passages
• A life-course approach to tackling noncommunicable diseases in women.1 passage
• A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer.71 passages
• A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.1 passage
• A meta-analysis of albuminuria as a surrogate endpoint for kidney failure.1 passage
• A microRNA-based dynamic risk score for type 1 diabetes.80 passages
• A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology.56 passages
• A multi-ancestry genetic study of pain intensity in 598,339 veterans.1 passage
• A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease.60 passages
• A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.143 passages
• A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.1 passage
• A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.1 passage
• A multimodal sleep foundation model for disease prediction.76 passages
• A multimodal vision foundation model for clinical dermatology.144 passages
• A multimodal whole-slide foundation model for pathology.157 passages
• A multisystem, cardio-renal investigation of post-COVID-19 illness.146 passages
• A neuroimaging biomarker for sustained experimental and clinical pain.1 passage
• A new clinical classification of acute myocardial infarction.1 passage
• A new phase of the Cancer Moonshot to end cancer as we know it.13 passages
• A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.1 passage
• A pan-African pathogen genomics data sharing platform to support disease outbreaks.15 passages
• A perfusable, multifunctional epicardial device improves cardiac function and tissue repair.1 passage
• A personal health large language model for sleep and fitness coaching.102 passages
• A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.74 passages
• A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.118 passages
• A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis.90 passages
• A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer.1 passage
• A portable thermal ablation device for cervical cancer prevention in a screen-and-treat setting: a randomized, noninferiority trial.81 passages
• A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels.63 passages
• A prognostic neural epigenetic signature in high-grade glioma.146 passages
• A prognostic risk score for development and spread of chronic pain.146 passages
• A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.79 passages
• A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.50 passages
• A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.121 passages
• A reinforcement learning model for AI-based decision support in skin cancer.32 passages
• A roadmap to increase diversity in genomic studies.46 passages
• A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.1 passage
• A shared neural basis underlying psychiatric comorbidity.105 passages
• A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.56 passages
• A simulation-based comparative effectiveness analysis of policies to improve global maternal health outcomes.57 passages
• A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.1 passage
• A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.1 passage
• A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.128 passages
• A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.1 passage
• A spinal cord neuroprosthesis for locomotor deficits due to Parkinson's disease.1 passage
• A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.76 passages
• A survey of COVID-19 vaccine acceptance across 23 countries in 2022.1 passage
• A sustainable house design to improve child health in rural Africa: a cluster-randomized controlled trial.1 passage
• A systematic review and meta-analysis of heat exposure impacts on maternal, fetal and neonatal health.53 passages
• A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.1 passage
• A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.95 passages
• A targeted antisense therapeutic approach for Hutchinson-Gilford progeria syndrome.1 passage
• A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk.1 passage
• A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.50 passages
• A time-stratified, case-crossover study of heat exposure and perinatal mortality from 16 hospitals in sub-Saharan Africa.55 passages
• A toolbox for surfacing health equity harms and biases in large language models.128 passages
• A toolkit for capturing a representative and equitable sample in health research.60 passages
• A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.1 passage
• A unified metric of human immune health.1 passage
• A vaccine chatbot intervention for parents to improve HPV vaccination uptake among middle school girls: a cluster randomized trial.71 passages
• A visual-language foundation model for computational pathology.1 passage
• A visual-language foundation model for pathology image analysis using medical Twitter.1 passage
• A wearable motion capture suit and machine learning predict disease progression in Friedreich's ataxia.101 passages
• AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.80 passages
• AAV gene therapy for Tay-Sachs disease.1 passage
• AAV gene therapy for autosomal recessive deafness 9: a single-arm trial.1 passage
• AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient.48 passages
• AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial.91 passages
• ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.1 passage
• AI framework for multidisease detection via retinal imaging.1 passage
• AI in health and medicine.1 passage
• AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.89 passages
• AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.54 passages
• AI-based diagnosis of acute aortic syndrome from noncontrast CT.76 passages
• AI-based differential diagnosis of dementia etiologies on multimodal data.140 passages
• AI-based large-scale screening of gastric cancer from noncontrast CT imaging.44 passages
• AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial.48 passages
• AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial.64 passages
• AI-driven multi-omics modeling of myalgic encephalomyelitis/chronic fatigue syndrome.1 passage
• AI-driven reclassification of multiple sclerosis progression.88 passages
• AI-enabled electrocardiography alert intervention and all-cause mortality: a pragmatic randomized clinical trial.1 passage
• AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer.114 passages
• AI-generated text may have a role in evidence-based medicine.1 passage
• AI-guided precision parenteral nutrition for neonatal intensive care units.74 passages
• AI-induced never-skilling in medical education.1 passage
• APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases.60 passages
• APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.1 passage
• AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.85 passages
• Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial.1 passage
• Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.42 passages
• Accelerated waning of the humoral response to COVID-19 vaccines in obesity.67 passages
• Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.63 passages
• Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis.1 passage
• Acute and postacute sequelae associated with SARS-CoV-2 reinfection.55 passages
• Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization.114 passages
• Adapted large language models can outperform medical experts in clinical text summarization.1 passage
• Adaptive selection at G6PD and disparities in diabetes complications.1 passage
• Addendum: Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus.2 passages
• Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial.1 passage
• Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.45 passages
• Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.1 passage
• Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.44 passages
• Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.1 passage
• Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results.1 passage
• Advancing conversational diagnostic AI with multimodal reasoning.121 passages
• Advancing equitable and sustainable urban health.1 passage
• Advancing global antibiotic research, development and access.1 passage
• Adverse childhood experiences and lifelong health.1 passage
• Air pollution interventions for health.1 passage
• Alcohol consumption and risks of more than 200 diseases in Chinese men.68 passages
• Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.1 passage
• Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.1 passage
• Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial.1 passage
• Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.1 passage
• Allogeneic approach unlocks CAR T cell benefits in solid tumors.1 passage
• Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.75 passages
• Altered perivascular fibroblast activity precedes ALS disease onset.1 passage
• Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.46 passages
• Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.39 passages
• An LLM chatbot to facilitate primary-to-specialist care transitions: a randomized controlled trial.88 passages
• An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.76 passages
• An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration.1 passage
• An adaptive AI-based virtual reality sports system for adolescents with excess body weight: a randomized controlled trial.185 passages
• An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.1 passage
• An agentic framework for autonomous scientific discovery in cancer pathology.1 passage
• An algorithmic approach to reducing unexplained pain disparities in underserved populations.1 passage
• An atlas of exposome-phenome associations in health and disease risk.96 passages
• An autoantibody signature predictive for multiple sclerosis.1 passage
• An automated histological classification system for precision diagnostics of kidney allografts.1 passage
• An early warning system for emerging SARS-CoV-2 variants.1 passage
• An ensemble of neural networks provides expert-level prenatal detection of complex congenital heart disease.1 passage
• An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy.1 passage
• An ethical plan for including forcibly displaced persons in omics and digital technology research.1 passage
• An evaluation framework for clinical use of large language models in patient interaction tasks.1 passage
• An evidence gap map of interventions for noncommunicable diseases and risk factors among children and adolescents.1 passage
• An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score.1 passage
• An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.1 passage
• An eyecare foundation model for clinical assistance: a randomized controlled trial.1 passage
• An implantable system to restore hemodynamic stability after spinal cord injury.160 passages
• An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.28 passages
• An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma.81 passages
• An integrated cell atlas of the lung in health and disease.160 passages
• An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease.90 passages
• An integrated tumor, immune and microbiome atlas of colon cancer.190 passages
• An international Delphi consensus for reporting of setting in psychedelic clinical trials.57 passages
• An international mega-analysis of psychedelic drug effects on brain circuit function.79 passages
• An online multidomain lifestyle intervention to prevent cognitive decline in at-risk older adults: a randomized controlled trial.1 passage
• An open-source framework for end-to-end analysis of electronic health record data.154 passages
• An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.102 passages
• An organotypic atlas of human vascular cells.125 passages
• Anakinra in Sanfilippo syndrome: a phase 1/2 trial.79 passages
• Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.24 passages
• Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.67 passages
• Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018.85 passages
• Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial.1 passage
• Angiopoietin-like 3-derivative LNA043 for cartilage regeneration in osteoarthritis: a randomized phase 1 trial.101 passages
• Anonymizing facial images to improve patient privacy.1 passage
• Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.1 passage
• Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.1 passage
• Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.1 passage
• Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.1 passage
• Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.1 passage
• Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein.1 passage
• Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial.60 passages
• Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial.64 passages
• Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial.54 passages
• Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.1 passage
• Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals.77 passages
• Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.63 passages
• Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.19 passages
• Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial.1 passage
• Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial.69 passages
• Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial.49 passages
• Antifungal heteroresistance causes prophylaxis failure and facilitates breakthrough Candida parapsilosis infections.1 passage
• Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis.84 passages
• Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.1 passage
• Antimalarial artesunate-mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial.57 passages
• Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.81 passages
• Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder.1 passage
• Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy.26 passages
• Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy.94 passages
• Anxiety-focused cognitive behavioral therapy delivered by non-specialists to prevent postnatal depression: a randomized, phase 3 trial.1 passage
• Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.1 passage
• Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.54 passages
• Artificial intelligence for direct-to-physician reporting of ambulatory electrocardiography.40 passages
• Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial.68 passages
• Artificial intelligence guided screening for cardiomyopathies in an obstetric population: a pragmatic randomized clinical trial.76 passages
• Artificial intelligence in drug development.1 passage
• Artificial intelligence in surgery.1 passage
• Artificial intelligence-enabled detection and assessment of Parkinson's disease using nocturnal breathing signals.105 passages
• Artificial intelligence-enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial.1 passage
• Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging.1 passage
• Assessment of medication self-administration using artificial intelligence.1 passage
• Association between pathologic response and survival after neoadjuvant therapy in lung cancer.57 passages
• Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery.83 passages
• Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer.57 passages
• Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.1 passage
• Association between the English National Health Service Diabetes Prevention Programme and incident multiple long-term conditions.54 passages
• Association of semaglutide with risk of suicidal ideation in a real-world cohort.1 passage
• Association of step counts over time with the risk of chronic disease in the All of Us Research Program.45 passages
• Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality.54 passages
• Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease.40 passages
• Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.99 passages
• Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.65 passages
• Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.43 passages
• Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.53 passages
• Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.1 passage
• Atlas of genetic and phenotypic associations across 42 female reproductive health diagnoses.1 passage
• Attributes and predictors of long COVID.1 passage
• Author Correction: A consensus immune dysregulation framework for sepsis and critical illnesses.1 passage
• Author Correction: A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD.1 passage
• Author Correction: A global survey of potential acceptance of a COVID-19 vaccine.5 passages
• Author Correction: A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features.1 passage
• Author Correction: A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus.1 passage
• Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.1 passage
• Author Correction: A shared neural basis underlying psychiatric comorbidity.1 passage
• Author Correction: AI-guided precision parenteral nutrition for neonatal intensive care units.1 passage
• Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.1 passage
• Author Correction: Anakinra in Sanfilippo syndrome: a phase 1/2 trial.1 passage
• Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.1 passage
• Author Correction: Artificial intelligence guided screening for cardiomyopathies in an obstetric population: a pragmatic randomized clinical trial.1 passage
• Author Correction: Association of step counts over time with the risk of chronic disease in the All of Us Research Program.1 passage
• Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.1 passage
• Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.1 passage
• Author Correction: Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations.1 passage
• Author Correction: Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries.1 passage
• Author Correction: Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.1 passage
• Author Correction: Clinical surveillance systems obscure the true cholera infection burden in an endemic region.1 passage
• Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.1 passage
• Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.1 passage
• Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.1 passage
• Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.1 passage
• Author Correction: Data-driven subtypes of polycystic ovary syndrome and their association with clinical outcomes.1 passage
• Author Correction: Delayed production of neutralizing antibodies correlates with fatal COVID-19.1 passage
• Author Correction: Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans.1 passage
• Author Correction: Digital consults in heart failure care: a randomized controlled trial.1 passage
• Author Correction: Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder.1 passage
• Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.1 passage
• Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.1 passage
• Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.1 passage
• Author Correction: Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial.1 passage
• Author Correction: Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.1 passage
• Author Correction: Enhanced cholera surveillance to improve vaccination campaign efficiency.1 passage
• Author Correction: Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial.1 passage
• Author Correction: Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.1 passage
• Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.1 passage
• Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.1 passage
• Author Correction: Genetically adjusted PSA levels for prostate cancer screening.1 passage
• Author Correction: Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death.1 passage
• Author Correction: Health effects associated with exposure to secondhand smoke: a Burden of Proof study.1 passage
• Author Correction: Heat-related mortality in Europe during the summer of 2022.1 passage
• Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.1 passage
• Author Correction: Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.1 passage
• Author Correction: In vivo base editing extends lifespan of a humanized mouse model of prion disease.1 passage
• Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.1 passage
• Author Correction: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.1 passage
• Author Correction: Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function.1 passage
• Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.1 passage
• Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.1 passage
• Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.1 passage
• Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.1 passage
• Author Correction: Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.1 passage
• Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.1 passage
• Author Correction: Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries.1 passage
• Author Correction: Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease.1 passage
• Author Correction: Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease.1 passage
• Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.1 passage
• Author Correction: Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants.1 passage
• Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.1 passage
• Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.1 passage
• Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.1 passage
• Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.1 passage
• Author Correction: Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.1 passage
• Author Correction: Prediction of recurrence risk in endometrial cancer with multimodal deep learning.1 passage
• Author Correction: Propagative α-synuclein seeds as serum biomarkers for synucleinopathies.1 passage
• Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.1 passage
• Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancers.1 passage
• Author Correction: Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.1 passage
• Author Correction: Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.1 passage
• Author Correction: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.1 passage
• Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege.1 passage
• Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.1 passage
• Author Correction: Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.1 passage
• Author Correction: Single-nucleus chromatin accessibility and transcriptomic map of breast tissues of women of diverse genetic ancestry.1 passage
• Author Correction: Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals.1 passage
• Author Correction: Spatial multiomic landscape of the human placenta at molecular resolution.1 passage
• Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.1 passage
• Author Correction: Subclassification of obesity for precision prediction of cardiometabolic diseases.1 passage
• Author Correction: Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.1 passage
• Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.1 passage
• Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.1 passage
• Author Correction: The impact of school opening model on SARS-CoV-2 community incidence and mortality.1 passage
• Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology.1 passage
• Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.2 passages
• Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.1 passage
• Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.1 passage
• Author Correction: What do journalists say about covering science during the COVID-19 pandemic?1 passage
• Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.91 passages
• Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.96 passages
• Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.104 passages
• Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.82 passages
• Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.77 passages
• Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys.1 passage
• Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.1 passage
• Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.55 passages
• Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.56 passages
• BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.38 passages
• BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.64 passages
• BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.118 passages
• BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.1 passage
• BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology.1 passage
• Bacterial SNPs in the human gut microbiome associate with host BMI.1 passage
• Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice.1 passage
• Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.47 passages
• Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.46 passages
• Benchmark evaluation of DeepSeek large language models in clinical decision-making.26 passages
• Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV.98 passages
• Benefits for children with suspected cancer from routine whole-genome sequencing.46 passages
• Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population.114 passages
• Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.49 passages
• Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.1 passage
• Better models mean better risk assessment for influenza A infection.1 passage
• Bilateral gene therapy in children with autosomal recessive deafness 9: single-arm trial results.72 passages
• Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.121 passages
• Bioaccumulation of microplastics in decedent human brains.23 passages
• Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.1 passage
• Biological and functional multimorbidity-from mechanisms to management.1 passage
• Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.70 passages
• Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.1 passage
• Biomarkers for neurodegenerative diseases.1 passage
• Bispecific T cell engager therapy for refractory rheumatoid arthritis.1 passage
• Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases.77 passages
• Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.1 passage
• Blood phosphorylated tau elevation as a biomarker in immunoglobulin light chain and transthyretin amyloidosis.34 passages
• Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial.1 passage
• Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.59 passages
• Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.52 passages
• Body composition and lung cancer-associated cachexia in TRACERx.49 passages
• Bodywide ecological interventions on cancer.1 passage
• Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.55 passages
• Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide.41 passages
• Brain aging patterns in a large and diverse cohort of 49,482 individuals.1 passage
• Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations.89 passages
• Brain lesions disrupting addiction map to a common human brain circuit.40 passages
• Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis.75 passages
• Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.100 passages
• Brown adipose tissue is associated with cardiometabolic health.1 passage
• Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study.68 passages
• Building genomic capacity for precision health in Africa.1 passage
• Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries.116 passages
• CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.86 passages
• CAR Treg cells: prime suspects in therapeutic resistance.1 passage
• CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.86 passages
• CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.1 passage
• CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.1 passage
• CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.66 passages
• CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.1 passage
• CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.76 passages
• CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer.1 passage
• CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.51 passages
• CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.84 passages
• CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.79 passages
• CONSORT 2025 statement: updated guideline for reporting randomized trials.1 passage
• COVID-19 and resilience of healthcare systems in ten countries.57 passages
• COVID-19 dynamics after a national immunization program in Israel.1 passage
• COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence.1 passage
• COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.73 passages
• COVID-19 vaccines: acting on the evidence.7 passages
• CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.109 passages
• CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia.1 passage
• CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.53 passages
• CSF tau microtubule-binding region identifies pathological changes in primary tauopathies.44 passages
• Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.85 passages
• Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.49 passages
• Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.1 passage
• Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.1 passage
• Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.76 passages
• CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs.77 passages
• Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events.41 passages
• Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective.1 passage
• Cardiotropic AAV gene therapy for heart failure: a phase 1 trial.63 passages
• Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.72 passages
• Causal machine learning for predicting treatment outcomes.1 passage
• Cell therapy for neurological disorders.1 passage
• Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.45 passages
• Cell-free DNA for the detection of kidney allograft rejection.69 passages
• Cell-free DNA methylome analysis for early preeclampsia prediction.1 passage
• Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.64 passages
• Cellular senescence and senolytics: the path to the clinic.1 passage
• Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.52 passages
• Cerebellar deep brain stimulation for chronic post-stroke motor rehabilitation: a phase I trial.57 passages
• Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases.1 passage
• Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.53 passages
• Cervical cancer screening using DNA methylation triage in a real-world population.37 passages
• Challenges and opportunities in NASH drug development.1 passage
• Changing climate and socioeconomic factors contribute to global antimicrobial resistance.1 passage
• Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells.1 passage
• Characterizing the physiology of circulatory arrest in humans.83 passages
• ChatGPT Health performance in a structured test of triage recommendations.29 passages
• Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis.1 passage
• Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.1 passage
• Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.1 passage
• Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.1 passage
• Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes.92 passages
• Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial.1 passage
• Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.52 passages
• Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.1 passage
• Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.37 passages
• Citizen science as an instrument for women's health research.1 passage
• City-level impact of extreme temperatures and mortality in Latin America.36 passages
• Citywide premarital genomic screening in a Middle Eastern population.71 passages
• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results.1 passage
• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.71 passages
• Climate change and health: three grand challenges.1 passage
• Climate change and infectious diseases.1 passage
• Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.63 passages
• Clinical applications of human organoids.1 passage
• Clinical decisions using AI must consider patient values.1 passage
• Clinical development of cancer vaccines.1 passage
• Clinical effects of Lewy body pathology in cognitively impaired individuals.47 passages
• Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.1 passage
• Clinical genetic variation across Hispanic populations in the Mexican Biobank.75 passages
• Clinical implementation of AI-based screening for risk for opioid use disorder in hospitalized adults.1 passage
• Clinical implementation of an AI-based prediction model for decision support for patients undergoing colorectal cancer surgery.80 passages
• Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer.1 passage
• Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California.1 passage
• Clinical surveillance systems obscure the true cholera infection burden in an endemic region.85 passages
• Clinical translation of microbiome research.1 passage
• Clinical utility of targeted RNA sequencing in cancer molecular diagnostics.1 passage
• Clinical validation of an AI-based blood testing device for diagnosis and prognosis of acute infection and sepsis.67 passages
• Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis.56 passages
• Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival.65 passages
• Clonal hematopoiesis is associated with protection from Alzheimer's disease.79 passages
• Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury.73 passages
• Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials.1 passage
• Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease.90 passages
• Closed-loop neuromodulation in an individual with treatment-resistant depression.1 passage
• Closing the accessibility gap to mental health treatment with a personalized self-referral chatbot.1 passage
• Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial.47 passages
• Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.1 passage
• Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.73 passages
• Cognitive behavioral therapy skills via a smartphone app for subthreshold depression among adults in the community: the RESiLIENT randomized controlled trial.103 passages
• Cognitive effects of Lewy body pathology in clinically unimpaired individuals.53 passages
• Collaboration between clinicians and vision-language models in radiology report generation.101 passages
• Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial.68 passages
• Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.82 passages
• Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.1 passage
• Combined endurance and resistance exercise training in heart failure with preserved ejection fraction: a randomized controlled trial.48 passages
• Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis.1 passage
• Communicating health information with visual displays.1 passage
• Community-integrated self-collected HPV-based cervix screening in a low-resource rural setting: a pragmatic, cluster-randomized trial.1 passage
• Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.1 passage
• Comorbidities, multimorbidity and COVID-19.1 passage
• Comparative benchmarking of the DeepSeek large language model on medical tasks and clinical reasoning.1 passage
• Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.65 passages
• Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial.40 passages
• Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial.1 passage
• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.1 passage
• Concerns about the Burden of Proof studies.7 passages
• Concerns about using a digital mask to safeguard patient privacy.1 passage
• Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.50 passages
• Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial.74 passages
• Consensus recommendations on how to assess the quality of surgical interventions.1 passage
• Considerations for patient and public involvement and engagement in health research.1 passage
• Consumer wearable devices for evaluation of heart rate control using digoxin versus beta-blockers: the RATE-AF randomized trial.44 passages
• Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy.50 passages
• Continuous glucose monitoring and intrapersonal variability in fasting glucose.1 passage
• Continuous neural control of a bionic limb restores biomimetic gait after amputation.84 passages
• Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.45 passages
• Coproducing health research with Indigenous peoples.1 passage
• Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.62 passages
• Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.72 passages
• Cranioencephalic functional lymphoid units in glioblastoma.83 passages
• Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.70 passages
• Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure.1 passage
• Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers.56 passages
• Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.35 passages
• Cytokine-mediated CAR T therapy resistance in AML.1 passage
• D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial.1 passage
• DASH-patterned groceries and effects on blood pressure in adults treated for hypertension: the GoFreshRx randomized trial.1 passage
• DASH4D diet for glycemic control and glucose variability in type 2 diabetes: a randomized crossover trial.1 passage
• DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism.55 passages
• Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.77 passages
• Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.1 passage
• Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.1 passage
• Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.46 passages
• Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.38 passages
• Daratumumab monotherapy for refractory lupus nephritis.28 passages
• Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.44 passages
• Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease.82 passages
• Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes.77 passages
• Data-driven prioritization of high-risk individuals for weight loss interventions.1 passage
• Data-driven risk stratification and precision management of pulmonary nodules detected on chest computed tomography.89 passages
• Data-driven subtypes of polycystic ovary syndrome and their association with clinical outcomes.69 passages
• Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.1 passage
• Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.1 passage
• Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year.1 passage
• Deciphering the etiology of the 2024 outbreak of undiagnosed febrile illness in Panzi, Democratic Republic of the Congo.59 passages
• Decoding the hallmarks of allograft dysfunction with a comprehensive pan-organ transcriptomic atlas.103 passages
• Deep learning in histopathology: the path to the clinic.1 passage
• Deep learning of HIV field-based rapid tests.1 passage
• Deep learning versus manual morphology-based embryo selection in IVF: a randomized, double-blind noninferiority trial.49 passages
• Deep learning-aided decision support for diagnosis of skin disease across skin tones.87 passages
• Deep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsies.1 passage
• Deep phenotyping of health-disease continuum in the Human Phenotype Project.1 passage
• Deep-learning-enabled protein-protein interaction analysis for prediction of SARS-CoV-2 infectivity and variant evolution.1 passage
• Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.62 passages
• Delayed production of neutralizing antibodies correlates with fatal COVID-19.1 passage
• Deleterious coding variation associated with autism is shared across ancestries.91 passages
• Delivering precision oncology to patients with cancer.1 passage
• Demographic bias in misdiagnosis by computational pathology models.1 passage
• Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses.1 passage
• Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.133 passages
• Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial.1 passage
• Determinants and inequities in healthy working life expectancy in China.1 passage
• Determinants of COVID-19 vaccination status and hesitancy among older adults in China.1 passage
• Determinants of COVID-19 vaccine fatigue.61 passages
• Determining the value of genomics in healthcare.1 passage
• Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases.1 passage
• Development and validation of a new algorithm for improved cardiovascular risk prediction.61 passages
• Development of a clinical polygenic risk score assay and reporting workflow.66 passages
• Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial.1 passage
• Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19.79 passages
• Diagnostic classification of childhood cancer using multiscale transcriptomics.110 passages
• Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.53 passages
• Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.1 passage
• Diet-microbiome associations in 10,068 individuals from the Human Phenotype Project to guide personalized nutrition.1 passage
• Dietary profiles and associated metabolic risk factors in India from the ICMR-INDIAB survey-21.86 passages
• Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans.83 passages
• Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring.42 passages
• Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial.102 passages
• Digital consults in heart failure care: a randomized controlled trial.54 passages
• Digital health for aging populations.1 passage
• Digital phenotyping could help detect autism.1 passage
• Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.1 passage
• Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial.29 passages
• Direct antimicrobial resistance prediction from clinical MALDI-TOF mass spectra using machine learning.1 passage
• Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis.93 passages
• Disease risk and healthcare utilization among ancestrally diverse groups in the Los Angeles region.1 passage
• Disparities in air pollution attributable mortality in the US population by race/ethnicity and sociodemographic factors.1 passage
• Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder.111 passages
• Disruption of the cerebrospinal fluid-plasma protein balance in cognitive impairment and aging.92 passages
• Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.1 passage
• Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy.1 passage
• Distinct monkeypox virus lineages co-circulating in humans before 2022.42 passages
• Distinction of lymphoid and myeloid clonal hematopoiesis.1 passage
• Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.44 passages
• Divergent age-associated and metabolism-associated gut microbiome signatures modulate cardiovascular disease risk.1 passage
• Diversity, equity and inclusion actions from the NCATS Clinical and Translational Science awarded programs.8 passages
• Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.39 passages
• Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes.1 passage
• Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.1 passage
• Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.53 passages
• Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.1 passage
• Drivers and determinants of strain dynamics following fecal microbiota transplantation.84 passages
• Drivers of adaptive evolution during chronic SARS-CoV-2 infections.64 passages
• Dual-energy lattice-tip ablation system for persistent atrial fibrillation: a randomized trial.54 passages
• Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.69 passages
• Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.108 passages
• Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.48 passages
• Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.63 passages
• Durable vision improvement after a single treatment with antisense oligonucleotide sepofarsen: a case report.1 passage
• Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.1 passage
• Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.87 passages
• Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.1 passage
• Dynamics and durability of HIV-1 neutralization are determined by viral replication.82 passages
• Dynamics of cognitive variability with age and its genetic underpinning in NIHR BioResource Genes and Cognition cohort participants.80 passages
• Dysbiosis of a microbiota-immune metasystem in critical illness is associated with nosocomial infections.64 passages
• Early detection of autism using digital behavioral phenotyping.85 passages
• Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics.1 passage
• Early detection of visual impairment in young children using a smartphone-based deep learning system.1 passage
• Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.1 passage
• Early treatment is a lifeline for infants with SMA.1 passage
• Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.47 passages
• Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.1 passage
• Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.85 passages
• Echocardiographic screening for heart failure and optimization of the care pathway for individuals with pacemakers: a randomized controlled trial.41 passages
• Education of healthcare professionals to improve guideline adherence in atrial fibrillation: the STEEER-AF cluster-randomized clinical trial.48 passages
• Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.69 passages
• Effect of a digital school-based intervention on adolescent family planning and reproductive health in Rwanda: a cluster-randomized trial.1 passage
• Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake.1 passage
• Effect of air pollution on the human immune system.9 passages
• Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies.58 passages
• Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.69 passages
• Effective control of SARS-CoV-2 transmission in Wanzhou, China.1 passage
• Effectiveness and safety of telehealth medication abortion in the USA.57 passages
• Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.45 passages
• Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile.26 passages
• Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.1 passage
• Effectiveness of bariatric metabolic surgery versus glucagon-like peptide-1 receptor agonists for prevention of congestive heart failure.1 passage
• Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.40 passages
• Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.1 passage
• Effects of a comprehensive antibiotic stewardship program on antibiotic prescribing for acute respiratory infections in rural facilities: a cluster randomized trial.1 passage
• Effects of a large-scale social media advertising campaign on holiday travel and COVID-19 infections: a cluster randomized controlled trial.68 passages
• Effects of a personalized nutrition program on cardiometabolic health: a randomized controlled trial.99 passages
• Effects of conditional cash transfers on tuberculosis incidence and mortality according to race, ethnicity and socioeconomic factors in the 100 Million Brazilian Cohort.55 passages
• Effects of daily multivitamin-multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial.1 passage
• Effects of early, late and self-selected time-restricted eating on visceral adipose tissue and cardiometabolic health in participants with overweight or obesity: a randomized controlled trial.1 passage
• Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study.62 passages
• Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.1 passage
• Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.45 passages
• Effects of the WHO Labour Care Guide on cesarean section in India: a pragmatic, stepped-wedge, cluster-randomized pilot trial.55 passages
• Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.47 passages
• Effects of urban living environments on mental health in adults.104 passages
• Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial.55 passages
• Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.42 passages
• Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.43 passages
• Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.1 passage
• Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.40 passages
• Efficacy of supermarket and web-based interventions for improving dietary quality: a randomized, controlled trial.46 passages
• Efficacy, public health impact and optimal use of the Takeda dengue vaccine.144 passages
• Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice.82 passages
• Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.1 passage
• Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.68 passages
• Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial.62 passages
• Electronic nudges for sustained influenza vaccination uptake in older adults: the nationwide randomized NUDGE-FLU-2 trial.1 passage
• Elevated uric acid levels, mortality and cognitive impairment in children with severe malaria.1 passage
• Eliminating opioid prescriptions from outpatient minimally invasive gynecologic surgery: a randomized trial.1 passage
• Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.69 passages
• Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.48 passages
• Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.34 passages
• Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa.49 passages
• Emerging diagnostics and therapeutics for Alzheimer disease.1 passage
• Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.1 passage
• Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.52 passages
• Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.1 passage
• Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.47 passages
• Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering.1 passage
• Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial.114 passages
• Engineered cellular immunotherapies in cancer and beyond.1 passage
• Enhanced cholera surveillance to improve vaccination campaign efficiency.93 passages
• Enhanced dynamic risk stratification of smoldering multiple myeloma.69 passages
• Enhancing pediatric access to cell and gene therapies.1 passage
• Enhancing the reliability and accuracy of AI-enabled diagnosis via complementarity-driven deferral to clinicians.1 passage
• Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.52 passages
• Epidemiological and genomic evolution of the ongoing outbreak of clade Ib mpox virus in the eastern Democratic Republic of the Congo.30 passages
• Epidural stimulation of the cervical spinal cord for post-stroke upper-limb paresis.1 passage
• Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure.74 passages
• Epigenomic dysregulation correlates with arachnoid cyst formation and neurodevelopmental symptoms.1 passage
• Equitable allocation of COVID-19 vaccines in the United States.1 passage
• Equitable implementation of a precision digital health program for glucose management in individuals with newly diagnosed type 1 diabetes.1 passage
• Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.1 passage
• Estimating future heat-related and cold-related mortality under climate change, demographic and adaptation scenarios in 854 European cities.46 passages
• Estimating the number of incorrect tuberculosis diagnoses in low- and middle-income countries.1 passage
• Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022.1 passage
• Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations.85 passages
• Evaluation and mitigation of the limitations of large language models in clinical decision-making.82 passages
• Evaluation of antimicrobial resistance governance across 193 countries to inform the 2026 Global Action Plan update.83 passages
• Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.1 passage
• Evidence for a role of Anopheles stephensi in the spread of drug- and diagnosis-resistant malaria in Africa.87 passages
• Evidence for iatrogenic transmission of Alzheimer's disease.1 passage
• Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.37 passages
• Evidence of monkeypox virus clade IIb lineage A.2.2 in the Republic of the Congo and co-circulation of clade Ia, Ib and clade IIb.33 passages
• Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.59 passages
• Evolution of delayed resistance to immunotherapy in a melanoma responder.1 passage
• Evolution of synchronous female bilateral breast cancers and response to treatment.94 passages
• Evolution, genetic diversity, and health.1 passage
• Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.117 passages
• Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.1 passage
• Evolutionary insight into the emergence of SARS-CoV-2 variants of concern.9 passages
• Exercise therapy and self-management support for individuals with multimorbidity: a randomized and controlled trial.71 passages
• Exergame and cognitive training for preventing falls in community-dwelling older people: a randomized controlled trial.1 passage
• Exome sequencing reveals genetic heterogeneity and clinically actionable findings in children with cerebral palsy.1 passage
• Exome-wide evaluation of rare coding variants using electronic health records identifies new gene-phenotype associations.1 passage
• Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.40 passages
• Extension of efficacy range for targeted malaria-elimination interventions due to spillover effects.87 passages
• External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial.65 passages
• Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents.1 passage
• Extreme geographic misalignment of healthcare resources and HIV treatment deserts in Malawi.79 passages
• Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials.123 passages
• Factors associated with healthy aging in Latin American populations.92 passages
• Factors driving provider adoption of the TREWS machine learning-based early warning system and its effects on sepsis treatment timing.1 passage
• Fair pathways to net-zero healthcare.1 passage
• Familial confounding in the associations between maternal health and autism.68 passages
• Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial.1 passage
• Feasibility and clinical utility of expanded genomic newborn screening in the Early Check program.69 passages
• Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation.55 passages
• Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers.75 passages
• Feasibility of multiomics tumor profiling for guiding treatment of melanoma.63 passages
• Feasibility, acceptability and clinical outcomes of the BabyScreen+ genomic newborn screening study.60 passages
• Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial.1 passage
• Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.1 passage
• Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.159 passages
• Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.113 passages
• Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial.95 passages
• Federated learning for predicting clinical outcomes in patients with COVID-19.1 passage
• Federated learning for predicting histological response to neoadjuvant chemotherapy in triple-negative breast cancer.1 passage
• Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.59 passages
• Ferric carboxymaltose for anemia in late pregnancy: a randomized controlled trial.73 passages
• Fetal cranial growth trajectories are associated with growth and neurodevelopment at 2 years of age: INTERBIO-21st Fetal Study.53 passages
• Financial incentives for COVID-19 vaccines in a rural low-resource setting: a cluster-randomized trial.111 passages
• Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.39 passages
• Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial.1 passage
• First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.71 passages
• First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy.1 passage
• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.1 passage
• First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.133 passages
• First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.1 passage
• First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.1 passage
• First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.43 passages
• First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.1 passage
• First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.47 passages
• First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.1 passage
• Five tenets for advancing evidence-based precision medicine.1 passage
• Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease.1 passage
• Four distinct trajectories of tau deposition identified in Alzheimer's disease.1 passage
• Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial.1 passage
• Fratricide-resistant CD7-CAR T cells in T-ALL.1 passage
• Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.1 passage
• Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.63 passages
• Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial.50 passages
• Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.50 passages
• GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.1 passage
• GDNF gene therapy for alcohol use disorder in male non-human primates.1 passage
• GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.1 passage
• GPT-4 assistance for improvement of physician performance on patient care tasks: a randomized controlled trial.1 passage
• Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.90 passages
• Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.1 passage
• Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.64 passages
• Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.1 passage
• Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results.81 passages
• Generative AI-based low-dose digital subtraction angiography for intra-operative radiation dose reduction: a randomized controlled trial.1 passage
• Generative artificial intelligence in medicine.1 passage
• Generative models improve fairness of medical classifiers under distribution shifts.145 passages
• Genetic and molecular landscape of comorbidities in people living with HIV.76 passages
• Genetic architecture and phenotypic diversity of oocyte and early embryo competence defects in female infertility.1 passage
• Genetic association analysis of 77,539 genomes reveals rare disease etiologies.88 passages
• Genetic basis of early onset and progression of type 2 diabetes in South Asians.76 passages
• Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.94 passages
• Genetic regulation across germline and somatic variation on the Y chromosome contributes to type 2 diabetes.90 passages
• Genetic risk factors have a substantial impact on healthy life years.106 passages
• Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer.1 passage
• Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities.107 passages
• Genetically adjusted PSA levels for prostate cancer screening.99 passages
• Genome-wide polygenic score to predict chronic kidney disease across ancestries.1 passage
• Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer.1 passage
• Genomic and transmission dynamics of the 2024 Marburg virus outbreak in Rwanda.32 passages
• Genomic autopsy to identify underlying causes of pregnancy loss and perinatal death.71 passages
• Genomic census of invasive nontyphoidal Salmonella infections reveals global and local human-to-human transmission.1 passage
• Genomic epidemiology of the 2025 mpox epidemic in Sierra Leone.69 passages
• Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.67 passages
• Genomic profiling informs diagnoses and treatment in vascular anomalies.1 passage
• Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses.93 passages
• Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.63 passages
• Genomics of perivascular space burden unravels early mechanisms of cerebral small vessel disease.87 passages
• Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.91 passages
• Geographic sources of ozone air pollution and mortality burden in Europe.41 passages
• Geographical shifting of cholera burden in Africa and its implications for disease control.131 passages
• Germline variants associated with toxicity to immune checkpoint blockade.1 passage
• Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial.1 passage
• Global and regional cancer burden attributable to modifiable risk factors to inform prevention.1 passage
• Global and regional estimates of orphans attributed to maternal cancer mortality in 2020.56 passages
• Global approaches to infectious disease surveillance and modeling.1 passage
• Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study.1 passage
• Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.75 passages
• Global distribution of research efforts, disease burden, and impact of US public funding withdrawal.84 passages
• Global genomic surveillance of monkeypox virus.49 passages
• Global lifetime estimates of expected and preventable gastric cancers across 185 countries.56 passages
• Global patterns and trends in breast cancer incidence and mortality across 185 countries.1 passage
• Global risk of selection and spread of Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions.69 passages
• Global vaccine development.1 passage
• Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c.53 passages
• Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study.1 passage
• Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990-2023: a Global Burden of Disease study.1 passage
• Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study.1 passage
• Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.1 passage
• Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes.38 passages
• Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.1 passage
• Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease.1 passage
• Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.1 passage
• Gut microbiome evolution from infancy to 8 years of age.1 passage
• Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.1 passage
• H5N1 influenza virus stability and transmission risk in raw milk and cheese.75 passages
• HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults.1 passage
• HLA-independent T cell receptors for targeting tumors with low antigen density.1 passage
• Harnessing EHR data for health research.1 passage
• Health and economic impacts of Lassa vaccination campaigns in West Africa.71 passages
• Health effects associated with consumption of processed meat, sugar-sweetened beverages and trans fatty acids: a Burden of Proof study.1 passage
• Health effects associated with consumption of unprocessed red meat: a Burden of Proof study.76 passages
• Health effects associated with exposure to intimate partner violence against women and childhood sexual abuse: a burden of proof study.85 passages
• Health effects associated with exposure to secondhand smoke: a Burden of Proof study.71 passages
• Health effects associated with smoking: a Burden of Proof study.77 passages
• Health effects associated with vegetable consumption: a Burden of Proof study.64 passages
• Health impacts of exposure to synthetic chemicals in food.1 passage
• Health impacts of microplastic and nanoplastic exposure.1 passage
• Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries.1 passage
• Healthcare system resilience and adaptability to pandemic disruptions in the United States.1 passage
• Heat exposure induced risks of preterm birth mediated by maternal hypertension.1 passage
• Heat-related mortality in Europe during 2023 and the role of adaptation in protecting health.1 passage
• Heat-related mortality in Europe during 2024 and health emergency forecasting to reduce preventable deaths.1 passage
• Heat-related mortality in Europe during the summer of 2022.43 passages
• Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection.1 passage
• Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain.1 passage
• Hemolysis contributes to anemia during long-duration space flight.31 passages
• Heterogeneity and predictors of the effects of AI assistance on radiologists.114 passages
• Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes.1 passage
• Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality.1 passage
• Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.57 passages
• Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.82 passages
• High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster.1 passage
• High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.1 passage
• High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.71 passages
• High-efficiency base editing in the retina in primates and human tissues.118 passages
• High-frequency neuromodulation improves obsessive-compulsive behavior.1 passage
• High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.136 passages
• High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity.133 passages
• Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.67 passages
• Hindsight is 2020? Lessons in global health governance one year into the pandemic.1 passage
• Hippocampal network activity forecasts epileptic seizures.1 passage
• Hobby engagement and mental wellbeing among people aged 65 years and older in 16 countries.69 passages
• Holistic evaluation of large language models for medical tasks with MedHELM.1 passage
• Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial.68 passages
• Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.1 passage
• Hospital admissions attributable to reduced air pollution due to clean-air policies in China.1 passage
• Housing modifications for heat adaptation, thermal comfort and malaria vector control in rural African settlements.93 passages
• How COVID-19 shaped mental health: from infection to pandemic effects.1 passage
• How Pakistan's community health workers use telemedicine for women's health.12 passages
• How better pandemic and epidemic intelligence will prepare the world for future threats.10 passages
• How to make cardiology clinical trials more inclusive.1 passage
• Human infections with highly pathogenic avian influenza A(H5N1) viruses in the United States from March 2024 to May 2025.1 passage
• Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.80 passages
• Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior.90 passages
• Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region.1 passage
• Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates.1 passage
• Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade.73 passages
• Humoral signatures of protective and pathological SARS-CoV-2 infection in children.1 passage
• Hypertension care cascades and reducing inequities in cardiovascular disease in low- and middle-income countries.1 passage
• Hypothalamic deep brain stimulation augments walking after spinal cord injury.1 passage
• IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies.97 passages
• IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.39 passages
• IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.50 passages
• IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial.77 passages
• IVF versus ICSI in patients without severe male factor infertility: a randomized clinical trial.57 passages
• Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.39 passages
• Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.50 passages
• Identification of a new orthonairovirus associated with human febrile illness in China.1 passage
• Identification of clinical disease trajectories in neurodegenerative disorders with natural language processing.91 passages
• Identification of genetic correlates of coronary artery disease in diverse ancestral populations.8 passages
• Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.1 passage
• Immune and metabolic effects of African heritage diets versus Western diets in men: a randomized controlled trial.104 passages
• Immune cell landscape in a human decedent receiving a pig liver xenograft.1 passage
• Immune determinants of COVID-19 disease presentation and severity.1 passage
• Immune history shapes human antibody responses to H5N1 influenza viruses.1 passage
• Immune impacts of fire smoke exposure.1 passage
• Immune profiling in a living human recipient of a gene-edited pig kidney.83 passages
• Immune reconstitution inflammatory syndrome drives emergence of HIV drug resistance from multiple anatomic compartments in a person living with HIV.1 passage
• Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.63 passages
• Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.38 passages
• Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.1 passage
• Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.25 passages
• Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.1 passage
• Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.93 passages
• Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19.1 passage
• Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results.1 passage
• Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults.50 passages
• Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.80 passages
• Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome.60 passages
• Impact of extreme weather events on healthcare utilization and mortality in the United States.1 passage
• Impact of the Human Cell Atlas on medicine.1 passage
• Impact of the ONCOBIOME network in cancer microbiome research.1 passage
• Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016-2020.49 passages
• Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.61 passages
• Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.59 passages
• Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson's disease.1 passage
• Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial.49 passages
• Implementation and evaluation of the Y-Check comprehensive adolescent health check-up intervention in Zimbabwe: a pre-post mixed-methods study.110 passages
• Implementation of a national AI technology program on cardiovascular outcomes and the health system.49 passages
• Implementation of pooled saliva tests for universal screening of cCMV infection.37 passages
• Implementation of the NHS England Lung Cancer Screening Programme over 5 years.57 passages
• In utero origin of myelofibrosis presenting in adult monozygotic twins.67 passages
• In vivo base editing extends lifespan of a humanized mouse model of prion disease.96 passages
• In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial.1 passage
• In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.1 passage
• In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.110 passages
• In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.59 passages
• Incident type 2 diabetes attributable to suboptimal diet in 184 countries.118 passages
• Increased frequency of repeat expansion mutations across different populations.90 passages
• Increased global integration in the brain after psilocybin therapy for depression.1 passage
• Individual and community-level risk for COVID-19 mortality in the United States.1 passage
• Individual variations in glycemic responses to carbohydrates and underlying metabolic physiology.81 passages
• Individualized therapy trials: navigating patient care, research goals and ethics.1 passage
• Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.1 passage
• Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity.1 passage
• Infant mental health services for birth and foster families of maltreated pre-school children in foster care (BeST?): a cluster-randomized phase 3 clinical effectiveness trial.58 passages
• Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.1 passage
• Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.1 passage
• Influence of COVID-19 on trust in routine immunization, health information sources and pandemic preparedness in 23 countries in 2023.24 passages
• Influence of believed AI involvement on the perception of digital medical advice.35 passages
• Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome.79 passages
• Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model.78 passages
• Influenza virus infection history shapes antibody responses to influenza vaccination.1 passage
• Inhaled particulate accumulation with age impairs immune function and architecture in human lung lymph nodes.1 passage
• Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child.1 passage
• Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.86 passages
• Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.1 passage
• Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.72 passages
• Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.1 passage
• Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial.42 passages
• Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.66 passages
• Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.1 passage
• Injury-specific factors in the cerebrospinal fluid regulate astrocyte plasticity in the human brain.91 passages
• Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.93 passages
• Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme.69 passages
• Insulin is expressed by enteroendocrine cells during human fetal development.1 passage
• Integrated community-based HIV and sexual and reproductive health services for youth: a cluster-randomized trial.84 passages
• Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma.121 passages
• Integrated genomic, epidemiologic investigation of Candida auris skin colonization in a skilled nursing facility.1 passage
• Integrated image-based deep learning and language models for primary diabetes care.90 passages
• Integrated multi-omics for rapid rare disease diagnosis on a national scale.82 passages
• Integrating liver endpoints in clinical trials of cardiovascular and kidney disease.1 passage
• Integrating the environmental and genetic architectures of aging and mortality.79 passages
• Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo.1 passage
• Integrative microbiomics in bronchiectasis exacerbations.1 passage
• Integrative multi-omics profiling in human decedents receiving pig heart xenografts.1 passage
• Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.88 passages
• Interactions between the lipidome and genetic and environmental factors in autism.142 passages
• Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.89 passages
• Intermittent fasting plus early time-restricted eating versus calorie restriction and standard care in adults at risk of type 2 diabetes: a randomized controlled trial.1 passage
• International multicenter validation of AI-driven ultrasound detection of ovarian cancer.65 passages
• Interpersonal conflicts, social media use and depression associated with protests.1 passage
• Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function.86 passages
• Interpretable inflammation landscape of circulating immune cells.156 passages
• Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.1 passage
• Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.1 passage
• Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial.50 passages
• Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial.77 passages
• Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.1 passage
• Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.1 passage
• Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.48 passages
• Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.55 passages
• Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma.1 passage
• Intratumoral heterogeneity in cancer progression and response to immunotherapy.1 passage
• Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.70 passages
• Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial.68 passages
• Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial.66 passages
• Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.1 passage
• Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.1 passage
• Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial.67 passages
• Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.59 passages
• Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.62 passages
• It's time to send children back to school.6 passages
• KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.1 passage
• LILRB3 genetic variation is associated with kidney transplant failure in African American recipients.1 passage
• LLM-assisted systematic review of large language models in clinical medicine.69 passages
• LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.1 passage
• Landscape of pathogenic mutations in premature ovarian insufficiency.81 passages
• Large floods drive changes in cause-specific mortality in the United States.61 passages
• Large language model-based biological age prediction in large-scale populations.1 passage
• Large language models for preventing medication direction errors in online pharmacies.138 passages
• Large language models in medicine.1 passage
• Large-scale genome-wide association study of coronary artery disease in genetically diverse populations.1 passage
• Large-scale pancreatic cancer detection via non-contrast CT and deep learning.107 passages
• Large-scale proteomics project seeks cures for neurodegenerative diseases.1 passage
• Lay community health worker-led care with mobile decision support for uncontrolled hypertension: a cluster-randomized trial.1 passage
• Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial.1 passage
• Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.1 passage
• Leukocyte telomere length in children born following blastocyst-stage embryo transfer.1 passage
• Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial.1 passage
• Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus.1 passage
• Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.1 passage
• Life expectancy and mortality in 363 cities of Latin America.63 passages
• Lifestyle interventions for cardiometabolic health.1 passage
• Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction.41 passages
• Lifetime risk and projected burden of dementia.1 passage
• Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.1 passage
• Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.72 passages
• Lingering cardiac involvement in previously well people after mild COVID-19.10 passages
• Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.1 passage
• Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity.79 passages
• Lipidome changes due to improved dietary fat quality inform cardiometabolic risk reduction and precision nutrition.110 passages
• Liquid biopsies across the cancer care continuum.1 passage
• Liquid biopsy epigenomic profiling for cancer subtyping.46 passages
• Liquid biopsy for the diagnosis of EBV-positive Burkitt's lymphoma in endemic areas.87 passages
• Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.66 passages
• Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.60 passages
• Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.1 passage
• Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.1 passage
• Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.89 passages
• Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.1 passage
• Long COVID after breakthrough SARS-CoV-2 infection.62 passages
• Long COVID in a prospective cohort of home-isolated patients.37 passages
• Long COVID includes breathing and reproductive problems and has a range of risk factors.10 passages
• Long COVID science, research and policy.1 passage
• Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency.1 passage
• Long-term cardiac pathology in individuals with mild initial COVID-19 illness.50 passages
• Long-term cardiovascular outcomes of COVID-19.68 passages
• Long-term ecological assessment of intracranial electrophysiology synchronized to behavioral markers in obsessive-compulsive disorder.1 passage
• Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.1 passage
• Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.63 passages
• Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.1 passage
• Long-term neurologic outcomes of COVID-19.72 passages
• Long-term neurological sequelae of SARS-CoV-2 infection.10 passages
• Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma.1 passage
• Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.1 passage
• Long-term risk of death after tuberculosis diagnosis and treatment.55 passages
• Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.80 passages
• Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.1 passage
• Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.47 passages
• Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.1 passage
• Longitudinal dynamics of clonal hematopoiesis identifies gene-specific fitness effects.55 passages
• Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit.45 passages
• Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.91 passages
• Looking beyond COVID-19 vaccine phase 3 trials.1 passage
• Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.68 passages
• Loss-of-function mutations in the melanocortin 4 receptor in a UK birth cohort.93 passages
• Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.54 passages
• Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.1 passage
• Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.1 passage
• Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.1 passage
• Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.88 passages
• Low-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trial.146 passages
• Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial.45 passages
• Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.1 passage
• Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.41 passages
• Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.67 passages
• MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.55 passages
• MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.63 passages
• MRI-based multi-organ clocks for healthy aging and disease assessment.103 passages
• MYC targeting by OMO-103 in solid tumors: a phase 1 trial.74 passages
• Machine learning for ECG diagnosis and risk stratification of occlusion myocardial infarction.61 passages
• Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations.88 passages
• Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary.1 passage
• Machine learning identifies long COVID patterns from electronic health records.10 passages
• Machine learning model to predict mental health crises from electronic health records.76 passages
• Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity.1 passage
• Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life.85 passages
• Magnesium-ibogaine therapy in veterans with traumatic brain injuries.85 passages
• Malaria is a cause of iron deficiency in African children.40 passages
• Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.63 passages
• Mapping the effectiveness and risks of GLP-1 receptor agonists.1 passage
• Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trial.68 passages
• Maternal diabetes and risk of attention-deficit/hyperactivity disorder in offspring in a multinational cohort of 3.6 million mother-child pairs.39 passages
• Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization.1 passage
• Maximizing researcher-policymaker engagement in global public health.1 passage
• Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.103 passages
• Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.113 passages
• Medical large language models are vulnerable to data-poisoning attacks.62 passages
• Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.99 passages
• Meta-prediction of coronary artery disease risk.1 passage
• Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease.1 passage
• Metabolomic profiles predict individual multidisease outcomes.71 passages
• Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma.1 passage
• Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.1 passage
• Microbial signals in primary and metastatic brain tumors.136 passages
• Microbiome and metabolome features of the cardiometabolic disease spectrum.84 passages
• Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development.83 passages
• Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals.1 passage
• Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals.1 passage
• Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.1 passage
• Microbiome-derived ethanol in nonalcoholic fatty liver disease.1 passage
• Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes.63 passages
• Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization.57 passages
• Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington's disease.176 passages
• Microglial activation and tau propagate jointly across Braak stages.1 passage
• Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease.135 passages
• Misinformation: susceptibility, spread, and interventions to immunize the public.1 passage
• Missed routine cardiovascular treatments during the COVID-19 pandemic.9 passages
• Mitochondrial DNA variants modulate N-formylmethionine, proteostasis and risk of late-onset human diseases.1 passage
• Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.1 passage
• Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.99 passages
• Modeling COVID-19 scenarios for the United States.75 passages
• Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India.41 passages
• Modeling global 80-80-80 blood pressure targets and cardiovascular outcomes.68 passages
• Modeling human adaptive immune responses with tonsil organoids.1 passage
• Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda.71 passages
• Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks.40 passages
• Modeling transmission of SARS-CoV-2 Omicron in China.59 passages
• Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.88 passages
• Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.100 passages
• Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma.70 passages
• Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.1 passage
• Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.60 passages
• Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.1 passage
• Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.68 passages
• Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.61 passages
• Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.43 passages
• Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae.104 passages
• Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial.124 passages
• Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.92 passages
• Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.70 passages
• Multi-ancestry polygenic mechanisms of type 2 diabetes.1 passage
• Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.111 passages
• Multi-omic definition of metabolic obesity through adipose tissue-microbiome interactions.96 passages
• Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection.1 passage
• Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia.103 passages
• Multi-organ landscape of therapy-resistant melanoma.90 passages
• Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer.1 passage
• Multimodal AI correlates of glucose spikes in people with normal glucose regulation, pre-diabetes and type 2 diabetes.61 passages
• Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.99 passages
• Multimodal assessment improves neuroprognosis performance in clinically unresponsive critical-care patients with brain injury.52 passages
• Multimodal biomedical AI.1 passage
• Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals.1 passage
• Multiomic analyses implicate a neurodevelopmental program in the pathogenesis of cerebral arachnoid cysts.1 passage
• Multiomic analyses uncover immunological signatures in acute and chronic coronary syndromes.167 passages
• Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology.61 passages
• Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.1 passage
• Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention.97 passages
• Multiomic spatial landscape of innate immune cells at human central nervous system borders.142 passages
• Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants.158 passages
• Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer.1 passage
• Multisystem involvement is common in post-COVID-19 syndrome.10 passages
• Mutations and variants of ONECUT1 in diabetes.1 passage
• Mutations in the U4 snRNA gene RNU4-2 cause one of the most prevalent monogenic neurodevelopmental disorders.25 passages
• Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis.1 passage
• Nationwide real-world implementation of AI for cancer detection in population-based mammography screening.60 passages
• Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial.51 passages
• Nature Medicine Commission on dialysis policy in low- and middle-income countries.1 passage
• Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.111 passages
• Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.92 passages
• Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.54 passages
• Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.53 passages
• Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.103 passages
• Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial.1 passage
• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.100 passages
• Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.52 passages
• Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery.1 passage
• Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.1 passage
• Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.74 passages
• Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.1 passage
• Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.48 passages
• Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.40 passages
• Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.90 passages
• Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.100 passages
• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.1 passage
• Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.89 passages
• Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.50 passages
• Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.1 passage
• Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.48 passages
• Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab.1 passage
• Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial.1 passage
• Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade.1 passage
• Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study.101 passages
• Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.1 passage
• Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.78 passages
• Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.1 passage
• Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition.77 passages
• Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination.30 passages
• Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination.1 passage
• Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.1 passage
• New and emerging approaches to treat psychiatric disorders.1 passage
• Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.50 passages
• Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.1 passage
• Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.60 passages
• Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.58 passages
• Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.1 passage
• Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.45 passages
• No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020.94 passages
• Non-invasive spinal cord electrical stimulation for arm and hand function in chronic tetraplegia: a safety and efficacy trial.57 passages
• Non-literacy biased, culturally fair cognitive detection tool in primary care patients with cognitive concerns: a randomized controlled trial.41 passages
• Noncanonical and mortality-defining toxicities of CAR T cell therapy.1 passage
• Noninvasive assessment of organ-specific and shared pathways in multi-organ fibrosis using T1 mapping.1 passage
• Noninvasive proteomic biomarkers for alcohol-related liver disease.88 passages
• Noninvasive, microbiome-based diagnosis of inflammatory bowel disease.73 passages
• Normothermic machine perfusion versus static cold storage in donation after circulatory death kidney transplantation: a randomized controlled trial.71 passages
• Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.80 passages
• Nowcasting epidemics of novel pathogens: lessons from COVID-19.1 passage
• Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce.1 passage
• Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk.69 passages
• Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.1 passage
• Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1/2 trial.1 passage
• Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.49 passages
• Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.60 passages
• Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.71 passages
• Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.1 passage
• Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.1 passage
• Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.1 passage
• Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.1 passage
• Optimal dietary patterns for healthy aging.45 passages
• Optimal dietary patterns for prevention of chronic disease.1 passage
• Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial.118 passages
• Optimizing risk-based breast cancer screening policies with reinforcement learning.1 passage
• Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates.58 passages
• Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.89 passages
• Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.1 passage
• Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.91 passages
• Orphanhood and caregiver death among children in the United States by all-cause mortality, 2000-2021.123 passages
• Outpatient reception via collaboration between nurses and a large language model: a randomized controlled trial.1 passage
• Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.1 passage
• PPIL4 is essential for brain angiogenesis and implicated in intracranial aneurysms in humans.1 passage
• PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.64 passages
• PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.1 passage
• Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance.1 passage
• Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.36 passages
• Pancreatic islet cryopreservation by vitrification achieves high viability, function, recovery and clinical scalability for transplantation.101 passages
• Pandemic monitoring with global aircraft-based wastewater surveillance networks.64 passages
• Parental inflammatory bowel disease and autism in children.64 passages
• Partial recovery of visual function in a blind patient after optogenetic therapy.1 passage
• Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease.108 passages
• Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial.1 passage
• Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.88 passages
• Pathogenic germline variations and cancer risks in pediatric patients referred for genetic testing.1 passage
• Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).1 passage
• Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes.1 passage
• Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.43 passages
• Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.81 passages
• Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial.95 passages
• Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.49 passages
• Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial.1 passage
• Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.55 passages
• Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.1 passage
• Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.39 passages
• Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.77 passages
• Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.49 passages
• Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.1 passage
• Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.1 passage
• Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.60 passages
• Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.1 passage
• Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.63 passages
• Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency.1 passage
• Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.82 passages
• Performance of plasma phosphorylated tau 181 and 217 in the community.1 passage
• Performance of the American Heart Association's PREVENT risk score for cardiovascular risk prediction in a multiethnic population.1 passage
• Performance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathy.1 passage
• Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial.40 passages
• Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.171 passages
• Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.105 passages
• Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.76 passages
• Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.49 passages
• Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial.1 passage
• Peripheral blood mononuclear cell respiratory function is associated with progressive glaucomatous vision loss.66 passages
• Persistent mutation burden drives sustained anti-tumor immune responses.85 passages
• Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.1 passage
• Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety.108 passages
• Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis.66 passages
• Personalized lab test models to quantify disease potentials in healthy individuals.1 passage
• Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.79 passages
• Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.1 passage
• Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.163 passages
• Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response.59 passages
• Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.69 passages
• Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.1 passage
• Phenome-wide associations of sleep characteristics in the Human Phenotype Project.1 passage
• Phenotypic effects of genetic variants associated with autism.87 passages
• Phenotypic signatures in clinical data enable systematic identification of patients for genetic testing.1 passage
• Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease.149 passages
• Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus.24 passages
• Physical activity as a modifiable risk factor in preclinical Alzheimer's disease.51 passages
• Physical activity for public health in the 21st century.88 passages
• Pig-to-human heart xenotransplantation in two recently deceased human recipients.1 passage
• Pig-to-human lung xenotransplantation into a brain-dead recipient.1 passage
• Pilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eating.53 passages
• Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial.1 passage
• Placental IGFBP1 levels during early pregnancy and the risk of insulin resistance and gestational diabetes.61 passages
• Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease.59 passages
• Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS.112 passages
• Plasma metabolites to profile pathways in noncommunicable disease multimorbidity.1 passage
• Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease.38 passages
• Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.65 passages
• Plasma proteome adaptations during feminizing gender-affirming hormone therapy.50 passages
• Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection.74 passages
• Plasma proteomic signature of the human menstrual cycle.1 passage
• Plasma proteomics links brain and immune system aging with healthspan and longevity.79 passages
• Pleconaril and ribavirin in new-onset type 1 diabetes: a phase 2 randomized trial.48 passages
• Political polarization and health.1 passage
• Polygenic embryo testing: understated ethics, unclear utility.1 passage
• Polygenic prediction of body mass index and obesity through the life course and across ancestries.79 passages
• Polygenic prediction of preeclampsia and gestational hypertension.1 passage
• Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors.1 passage
• Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer.128 passages
• Population-based, first-tier genomic newborn screening in the maternity ward.56 passages
• Population-scale genomic medicine with the Hong Kong Genome Project.1 passage
• Population-wide diversity and stability of serum antibody epitope repertoires against human microbiota.1 passage
• Post-acute COVID-19 syndrome.1 passage
• Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.1 passage
• Postacute sequelae of COVID-19 at 2 years.67 passages
• Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction.63 passages
• Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection.1 passage
• Powered hip exoskeleton improves walking economy in individuals with above-knee amputation.1 passage
• Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.60 passages
• Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans.34 passages
• Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial.108 passages
• Precision nutrition for cardiometabolic diseases.1 passage
• Precision public health in the era of genomics and big data.1 passage
• Precision-guided treatment in high-risk pediatric cancers.61 passages
• Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a).1 passage
• Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.106 passages
• Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.78 passages
• Predicting referral need for febrile children in low-resource community settings in South and Southeast Asia.109 passages
• Predicting the efficacy of variant-modified COVID-19 vaccine boosters.1 passage
• Prediction of DNA methylation-based tumor types from histopathology in central nervous system tumors with deep learning.1 passage
• Prediction of brain metastasis development with DNA methylation signatures.78 passages
• Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.99 passages
• Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.1 passage
• Prediction of mental health risk in adolescents.1 passage
• Prediction of recurrence risk in endometrial cancer with multimodal deep learning.94 passages
• Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning.115 passages
• Predictors of COVID-19 epidemics in countries of the World Health Organization African Region.52 passages
• Preeclampsia risk prediction from prenatal cell-free DNA screening.76 passages
• Prevalence of chromosomal alterations in first-trimester spontaneous pregnancy loss.71 passages
• Prevalence of comorbidities in individuals with neurodevelopmental disorders from the aggregated phenomics data of 51,227 pediatric individuals.1 passage
• Prevalence of smoldering multiple myeloma based on nationwide screening.1 passage
• Preventing HIV in women in Africa.35 passages
• Prevention of type 2 diabetes through prediabetes remission without weight loss.62 passages
• Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial.98 passages
• Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers.59 passages
• Priorities for cancer research in low- and middle-income countries: a global perspective.1 passage
• Prisons as ecological drivers of fitness-compensated multidrug-resistant Mycobacterium tuberculosis.1 passage
• Prognostic value of polygenic risk scores for adults with psychosis.1 passage
• Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.1 passage
• Programmable antivirals to target conserved essential shapes in pandemic viral genomes.9 passages
• Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.122 passages
• Propagative α-synuclein seeds as serum biomarkers for synucleinopathies.72 passages
• Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction.1 passage
• Prospective implementation of AI-assisted screen reading to improve early detection of breast cancer.41 passages
• Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma.1 passage
• Prospective prenatal cell-free DNA screening for genetic conditions of heterogenous etiologies.1 passage
• Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis.1 passage
• Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors.69 passages
• Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations.80 passages
• Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risks.63 passages
• Proteomic changes upon treatment with semaglutide in individuals with obesity.58 passages
• Proteomic risk score for early prediction of kidney disease progression in individuals with APOL1 high-risk genotypes.71 passages
• Proteomic signatures for identification of impaired glucose tolerance.1 passage
• Proteomic signatures improve risk prediction for common and rare diseases.65 passages
• Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.49 passages
• Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.1 passage
• Publisher Correction: Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial.1 passage
• Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.1 passage
• Publisher Correction: Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.1 passage
• Publisher Correction: Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.1 passage
• Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.1 passage
• Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.1 passage
• Publisher Correction: Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial.1 passage
• Publisher Correction: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses.1 passage
• Publisher Correction: Interpretable inflammation landscape of circulating immune cells.1 passage
• Publisher Correction: Monitoring key epidemiological parameters of SARS-CoV-2 transmission.1 passage
• Publisher Correction: Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.1 passage
• Publisher Correction: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection.1 passage
• Publisher Correction: Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease.1 passage
• Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.1 passage
• Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.1 passage
• Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.1 passage
• Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease.1 passage
• Publisher Correction: Reliability of LLMs as medical assistants for the general public: a randomized preregistered study.1 passage
• Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.1 passage
• Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer.1 passage
• Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study.59 passages
• Putting mental health center stage.1 passage
• Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic.10 passages
• Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.102 passages
• RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial.61 passages
• RANO criteria for response assessment of brain metastases based on amino acid PET imaging.1 passage
• RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.98 passages
• RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.64 passages
• Rapid brain tumor classification from sparse epigenomic data.305 passages
• Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance.41 passages
• Rapid expansion of genotype D1.1 A(H5N1) influenza viruses in wild birds across North America during the 2024 migratory season.36 passages
• Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids.1 passage
• Rare and common genetic determinants of metabolic individuality and their effects on human health.90 passages
• Real-time alerting system for COVID-19 and other stress events using wearable data.54 passages
• Real-time surveillance system for patient deterioration: a pragmatic cluster-randomized controlled trial.1 passage
• Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.58 passages
• Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.72 passages
• Real-world clinical utility of tumor whole-genome sequencing in solid cancers.80 passages
• Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection.64 passages
• Real-world effectiveness of a single dose of mpox vaccine in males.31 passages
• Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China.44 passages
• Recent successes in heart failure treatment.1 passage
• Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial.60 passages
• Recommendations to address respondent burden associated with patient-reported outcome assessment.1 passage
• Recommendations to promote equity, diversity and inclusion in decentralized clinical trials.1 passage
• Redefining critical illness.1 passage
• Reduced-energy diet in women with gestational diabetes: the dietary intervention in gestational diabetes DiGest randomized clinical trial.65 passages
• Reduction in life expectancy in Brazil after COVID-19.1 passage
• Reductions in smoking due to ratification of the Framework Convention for Tobacco Control in 171 countries.50 passages
• Reevaluating the role of education on cognitive decline and brain aging in longitudinal cohorts across 33 Western countries.1 passage
• Regenerative and restorative medicine for eye disease.1 passage
• Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.103 passages
• Reliability of LLMs as medical assistants for the general public: a randomized preregistered study.69 passages
• Remote monitoring of heart failure exacerbations using a smartwatch.93 passages
• Remotely delivered weight management for people with long COVID and overweight: the randomized wait-list-controlled ReDIRECT trial.73 passages
• Remove obstacles to sharing health data with researchers outside of the European Union.20 passages
• Reply to: Concerns about the Burden of Proof studies.7 passages
• Reply to: Concerns about using a digital mask to safeguard patient privacy.5 passages
• Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI.1 passage
• Reporting guidelines for human microbiome research: the STORMS checklist.1 passage
• Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist.1 passage
• Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.52 passages
• Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.1 passage
• Resetting autoimmune disease with CAR cell therapies.1 passage
• Reshaping transplantation with AI, emerging technologies and xenotransplantation.1 passage
• Resilience and brain health in global populations.1 passage
• Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.64 passages
• Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.1 passage
• Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.116 passages
• Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.1 passage
• Retrieval of vector integration sites from cell-free DNA.1 passage
• Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium.31 passages
• Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic.46 passages
• Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.43 passages
• Risk factors associated with heatwave mortality in Chinese adults over 65 years.1 passage
• Risk factors for PICU admission and death among children and young people hospitalized with COVID-19 and PIMS-TS in England during the first pandemic year.1 passage
• Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults.65 passages
• Risk-based lung cancer screening performance in a universal healthcare setting.1 passage
• Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.79 passages
• Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.103 passages
• Robust airway microbiome signatures in acute respiratory failure and hospital-acquired pneumonia.1 passage
• Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach.1 passage
• Role of anticoagulation therapy in modifying stroke risk associated with new-onset atrial fibrillation after non-cardiac surgery.1 passage
• SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.1 passage
• SARS-CoV-2 correlates of protection from infection against variants of concern.1 passage
• SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.48 passages
• SARS-CoV-2 infection of the oral cavity and saliva.1 passage
• SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.1 passage
• SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.86 passages
• SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination.70 passages
• SPIRIT 2025 statement: updated guideline for protocols of randomized trials.1 passage
• Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.48 passages
• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials.1 passage
• Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.1 passage
• Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.66 passages
• Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.76 passages
• Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.1 passage
• Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.77 passages
• Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.50 passages
• Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.47 passages
• Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.1 passage
• Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial.92 passages
• Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.1 passage
• Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis.62 passages
• Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial.1 passage
• Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.1 passage
• Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial.1 passage
• Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study.64 passages
• Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.121 passages
• Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.76 passages
• Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.1 passage
• Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.1 passage
• Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.72 passages
• Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.78 passages
• Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.1 passage
• Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial.1 passage
• Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.55 passages
• Scaling medical AI across clinical contexts.1 passage
• Screening and diagnosis of cardiovascular disease using artificial intelligence-enabled cardiac magnetic resonance imaging.116 passages
• Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.1 passage
• Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.1 passage
• Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic TH1 cell responses in Crohn's disease.93 passages
• Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations.88 passages
• Self-care interventions for women's health and well-being.1 passage
• Self-help mobile messaging intervention for depression among older adults in resource-limited settings: a randomized controlled trial.62 passages
• Self-improving generative foundation model for synthetic medical image generation and clinical applications.1 passage
• Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease.1 passage
• Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial.1 passage
• Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.40 passages
• Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.1 passage
• Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.34 passages
• Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.1 passage
• Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.1 passage
• Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.1 passage
• Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.1 passage
• Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.1 passage
• Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections.62 passages
• Severe disease during both primary and secondary dengue virus infections in pediatric populations.1 passage
• Sex differences in brain protein expression and disease.73 passages
• Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.1 passage
• Sex-specific genetic architecture of blood pressure.1 passage
• Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.93 passages
• Shared and specific blood biomarkers for multimorbidity.79 passages
• Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.246 passages
• Simulation-based estimates and projections of global, regional and country-level maternal mortality by cause, 1990-2050.69 passages
• Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial.30 passages
• Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases.1 passage
• Single-cell atlas of the developing Down syndrome brain cortex.112 passages
• Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma.1 passage
• Single-cell guided prenatal derivation of primary fetal epithelial organoids from human amniotic and tracheal fluids.115 passages
• Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics.1 passage
• Single-cell multi-omics analysis of the immune response in COVID-19.126 passages
• Single-cell profiling of the human endometrium in polycystic ovary syndrome.87 passages
• Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis.1 passage
• Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.62 passages
• Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.1 passage
• Single-nucleus chromatin accessibility and transcriptomic map of breast tissues of women of diverse genetic ancestry.71 passages
• Sixteen novel lineages of SARS-CoV-2 in South Africa.1 passage
• Sleep patterns and risk of chronic disease as measured by long-term monitoring with commercial wearable devices in the All of Us Research Program.52 passages
• Sleep spindles as a predictor of cognitive motor dissociation and recovery of consciousness after acute brain injury.1 passage
• Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial.1 passage
• Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment.91 passages
• Social disadvantage accelerates aging.100 passages
• Sociodemographic biases in medical decision making by large language models.1 passage
• Socioeconomic and energy transition disparities in air pollution-related mortality across Europe.1 passage
• Soft robotic apparel to avert freezing of gait in Parkinson's disease.1 passage
• Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.60 passages
• Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis.82 passages
• Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.72 passages
• Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.104 passages
• Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.1 passage
• Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals.115 passages
• Spatial multiomic landscape of the human placenta at molecular resolution.128 passages
• Spatially resolved single-cell atlas unveils a distinct cellular signature of fatal lung COVID-19 in a Malawian population.106 passages
• Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.70 passages
• State-dependent responses to intracranial brain stimulation in a patient with depression.1 passage
• Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.94 passages
• Stem cell therapies for diabetes.1 passage
• Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes.1 passage
• Strategies for shortening tuberculosis therapy.1 passage
• Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.140 passages
• Strengthening Africa's brain health and economic resilience.1 passage
• Subclassification of obesity for precision prediction of cardiometabolic diseases.83 passages
• Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.1 passage
• Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.51 passages
• Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial.73 passages
• Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer.55 passages
• Suicide risk and mortality among patients with cancer.1 passage
• Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial.59 passages
• Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide.1 passage
• Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial.1 passage
• Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.1 passage
• Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.78 passages
• Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission.57 passages
• Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.49 passages
• Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo.30 passages
• Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.1 passage
• Swarm learning for decentralized artificial intelligence in cancer histopathology.46 passages
• Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.1 passage
• Symptoms and risk factors for long COVID in non-hospitalized adults.57 passages
• Syndemics and clinical science.1 passage
• Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.1 passage
• Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency.42 passages
• Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome.1 passage
• T and B cell responses against Epstein-Barr virus in primary sclerosing cholangitis.96 passages
• T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.1 passage
• T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.1 passage
• T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.1 passage
• T cell malignancies after CAR T cell therapy in the DESCAR-T registry.1 passage
• T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection.68 passages
• TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.1 passage
• TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial.53 passages
• TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.75 passages
• Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial.63 passages
• Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease.1 passage
• Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis.30 passages
• Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.1 passage
• Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial.1 passage
• Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.1 passage
• Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.46 passages
• Targeting KRAS in cancer.1 passage
• Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.1 passage
• Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.1 passage
• Targeting metastatic cancer.1 passage
• Targeting of HIF2-driven cachexia in kidney cancer.116 passages
• Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial.62 passages
• Targeting the gut and tumor microbiota in cancer.1 passage
• Task-sharing and telemedicine delivery of psychotherapy to treat perinatal depression: a pragmatic, noninferiority randomized trial.80 passages
• Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.51 passages
• Technology-assisted cognitive-behavioral therapy for perinatal depression delivered by lived-experience peers: a cluster-randomized noninferiority trial.84 passages
• Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial.1 passage
• Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial.67 passages
• Temporal order of clinical and biomarker changes in familial frontotemporal dementia.1 passage
• Thalamic deep brain stimulation in traumatic brain injury: a phase 1, randomized feasibility study.1 passage
• The All of Us Research Program is an opportunity to enhance the diversity of US biomedical research.1 passage
• The All of Us Research Program's wearables dataset.1 passage
• The Burden of Proof studies: assessing the evidence of risk.94 passages
• The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.47 passages
• The Global Burden of Disease Study at 30 years.1 passage
• The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.77 passages
• The IDEAL framework for surgical robotics: development, comparative evaluation and long-term monitoring.1 passage
• The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation.50 passages
• The NCI-MATCH trial: lessons for precision oncology.1 passage
• The NOTCH3 extracellular domain is a serum biomarker for pulmonary arterial hypertension.75 passages
• The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.36 passages
• The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.135 passages
• The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.33 passages
• The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.47 passages
• The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.40 passages
• The STARD-AI reporting guideline for diagnostic accuracy studies using artificial intelligence.1 passage
• The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial.1 passage
• The TRIPOD-LLM reporting guideline for studies using large language models.1 passage
• The Tuberculosis Drug Accelerator at year 10: what have we learned?1 passage
• The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial.1 passage
• The WHO global landscape of cancer clinical trials.1 passage
• The Yearbook: 11 early-career researchers to watch.11 passages
• The airway microbiome mediates the interaction between environmental exposure and respiratory health in humans.1 passage
• The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.1 passage
• The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.1 passage
• The artificial sweetener erythritol and cardiovascular event risk.1 passage
• The arts for disease prevention and health promotion: a systematic review.1 passage
• The burden of diabetes-associated multiple long-term conditions on years of life spent and lost.46 passages
• The distribution of cellular turnover in the human body.1 passage
• The economic value of reducing avoidable mortality.1 passage
• The economic value of reducing mortality due to noncommunicable diseases and injuries.59 passages
• The economics of investing in women and health.1 passage
• The effects of tobacco control policies on global smoking prevalence.41 passages
• The expanding landscape of GLP-1 medicines.1 passage
• The exposome of brain aging across 34 countries.1 passage
• The exposome of healthy and accelerated aging across 40 countries.1 passage
• The fasciola cinereum of the hippocampal tail as an interventional target in epilepsy.62 passages
• The future of diagnostics in Africa.1 passage
• The future of early cancer detection.1 passage
• The global macroeconomic burden of diabetes mellitus.87 passages
• The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk.1 passage
• The gut-brain axis underlying hepatic encephalopathy in liver cirrhosis.1 passage
• The health risks of generative AI-based wellness apps.1 passage
• The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome.67 passages
• The impact of interactive text communication on neonatal mortality in Kenya: a randomized controlled trial.1 passage
• The impact of school opening model on SARS-CoV-2 community incidence and mortality.1 passage
• The impact of the COVID-19 pandemic on cardiovascular disease prevention and management.1 passage
• The infant gut virome is associated with preschool asthma risk independently of bacteria.1 passage
• The landscape of cancer research and cancer care in China.1 passage
• The landscape of mRNA nanomedicine.1 passage
• The limits of fair medical imaging AI in real-world generalization.93 passages
• The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.1 passage
• The next generation of COVID-19 vaccines.1 passage
• The next generation of evidence-based medicine.1 passage
• The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology.1 passage
• The promise of precision medicine in rheumatology.1 passage
• The proteogenomic landscape of the human kidney and implications for cardio-kidney-metabolic health.1 passage
• The recombinant shingles vaccine is associated with lower risk of dementia.35 passages
• The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration.110 passages
• The science of psychedelic medicine.1 passage
• The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial.61 passages
• The transcriptional and regulatory identity of erythropoietin producing cells.1 passage
• The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.1 passage
• The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.79 passages
• The value of standards for health datasets in artificial intelligence-based applications.71 passages
• Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results.1 passage
• Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.1 passage
• Three-year outcomes of post-acute sequelae of COVID-19.61 passages
• Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk.58 passages
• Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.1 passage
• Time to make rare disease diagnosis accessible to all.1 passage
• Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.1 passage
• Time-restricted eating for body weight management in women with polycystic ovary syndrome: a randomized controlled trial.1 passage
• Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.116 passages
• Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.48 passages
• Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.21 passages
• Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.74 passages
• Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.37 passages
• Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.1 passage
• Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.1 passage
• Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.42 passages
• Tissue perfusion pressure enables continuous hemodynamic evaluation and risk prediction in the intensive care unit.1 passage
• To curb COVID-19, global health must go local.6 passages
• To tackle diabetes, science and health systems must take into account social context.1 passage
• Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.1 passage
• Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.1 passage
• Toward a biological definition of neuronal and glial synucleinopathies.1 passage
• Toward expert-level medical question answering with large language models.98 passages
• Toward personalized treatment approaches for non-small-cell lung cancer.1 passage
• Toward universal health coverage in the post-COVID-19 era.1 passage
• Towards a general-purpose foundation model for computational pathology.1 passage
• Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain.1 passage
• Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.1 passage
• Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition.1 passage
• Transcriptional mediators of treatment resistance in lethal prostate cancer.69 passages
• Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia.52 passages
• Transferability of genetic risk scores in African populations.23 passages
• Transmission dynamics of Oropouche virus in Latin America and the Caribbean.1 passage
• Transmission dynamics of the 2022 mpox epidemic in New York City.65 passages
• Transparent medical image AI via an image-text foundation model grounded in medical literature.1 passage
• Transplantation of a genetically modified porcine heart into a live human.1 passage
• Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial.105 passages
• Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.45 passages
• Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.54 passages
• Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.42 passages
• Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.55 passages
• Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.68 passages
• Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.41 passages
• Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning.1 passage
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.58 passages
• Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.45 passages
• Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.77 passages
• Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.52 passages
• Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.66 passages
• Tumor inflammation-associated neurotoxicity.1 passage
• Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.1 passage
• Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.71 passages
• Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease.16 passages
• Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial.37 passages
• Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity.1 passage
• Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: a randomized, crossover trial.88 passages
• Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma.41 passages
• Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.137 passages
• Uncovering links between parental inflammatory bowel disease and autism in children.10 passages
• Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations.45 passages
• Underrepresentation of blind and deaf participants in the All of Us Research Program.1 passage
• Understanding the provenance and quality of methods is essential for responsible reuse of FAIR data.7 passages
• Unexplained post-acute infection syndromes.1 passage
• Unidirectional association of clonal hematopoiesis with atherosclerosis development.52 passages
• Upregulation of reward mesolimbic activity and immune response to vaccination: a randomized controlled trial.1 passage
• Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.85 passages
• Vaccine development for emerging infectious diseases.1 passage
• Vaccine development needs a boost.6 passages
• Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.30 passages
• Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial.68 passages
• Validation of biomarkers of aging.1 passage
• Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.1 passage
• Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases.105 passages
• Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa.1 passage
• Varicella-zoster virus reactivation and the risk of dementia.58 passages
• Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.64 passages
• Viral and host mediators of non-suppressible HIV-1 viremia.61 passages
• Viral genetic clustering and transmission dynamics of the 2022 mpox outbreak in Portugal.52 passages
• Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.1 passage
• Virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: a randomized controlled trial.102 passages
• Vision-language foundation model for echocardiogram interpretation.48 passages
• Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.55 passages
• Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy.78 passages
• Wearable movement-tracking data identify Parkinson's disease years before clinical diagnosis.1 passage
• Wearable sensor data and self-reported symptoms for COVID-19 detection.1 passage
• Wearable sensors enable personalized predictions of clinical laboratory measurements.1 passage
• Western diets and chronic diseases.1 passage
• Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.65 passages
• Whole-genome risk prediction of common diseases in human preimplantation embryos.41 passages
• Why menstrual cycle irregularities belong in brain research.1 passage
• Wireless broadband acousto-mechanical sensing system for continuous physiological monitoring.1 passage
• Women's health and rights in the twenty-first century.1 passage
• XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis.1 passage
• YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.1 passage
• Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.1 passage
• Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.69 passages
• [11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial.129 passages
• ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.84 passages
• ctDNA-based molecular residual disease and survival in resectable colorectal cancer.59 passages
• mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.26 passages
• mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.1 passage
• mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial.1 passage
• p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.80 passages